## Henryk Stepien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8331279/publications.pdf

Version: 2024-02-01

111	1,801	23	35
papers	citations	h-index	g-index
113	113	113	1829
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms. Pharmaceuticals, 2020, 13, 354.	1.7	3
2	High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms. Endocrine Pathology, 2020, 31, 264-273.	5.2	6
3	Elevated serum concentrations of IGF-1 and IGF-1R in patients with thyroid cancers. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2020, 164, 77-83.	0.2	7
4	Dysregulation in IGF-1R, FGFR4 and $\hat{l}^2$ Klotho signaling in patients with medullary thyroid cancer. Neuroendocrinology Letters, 2019, 40, 29-35.	0.2	2
5	Alteration in the serum concentrations of FGF19, FGFR4 and $\hat{l}^2$ Klotho in patients with thyroid cancer. Cytokine, 2018, 105, 32-36.	1.4	18
6	Estimation of vitamin D status in patients with secondary and primary hypothyroidism of different etiology. Neuroendocrinology Letters, 2018, 38, 565-564.	0.2	2
7	Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. Disease Markers, 2017, 2017, 1-5.	0.6	18
8	Somatostatin Analogs and Tumor Localization Do Not Influence Vitamin D Concentration in Patients with Neuroendocrine Tumors. Nutrition and Cancer, 2016, 68, 428-434.	0.9	14
9	Concentration of angiopoietins 1 and 2 and their receptor Tie-2 in peripheral blood in patients with chronic obstructive pulmonary disease. Postepy Dermatologii I Alergologii, 2015, 6, 443-448.	0.4	6
10	Decreased serum level of IL-7 in patients with active Graves' disease. Cytokine, 2015, 75, 373-379.	1.4	5
11	Reduced plasma level of diazepam-binding inhibitor (DBI) in patients with morbid obesity. Endocrine, 2015, 49, 859-862.	1.1	8
12	Interferon alpha and rapamycin inhibit the growth of carcinoid and medullary thyroid cancer in vitro. Pharmacological Reports, 2014, 66, 624-629.	1.5	5
13	Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine, 2013, 64, 490-493.	1.4	24
14	Immunohistochemical detection of follicle stimulating hormone receptor (FSHR) in neuroendocrine tumours. Endokrynologia Polska, 2013, 64, 268-271.	0.3	9
15	Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro. Endokrynologia Polska, 2013, 64, 368-374.	0.3	12
16	Elevated Peripheral Blood Plasma Concentrations of Tie-2 and Angiopoietin 2 in Patients with Neuroendocrine Tumors. International Journal of Molecular Sciences, 2012, 13, 1444-1460.	1.8	17
17	Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 56-63.	0.8	8
18	Modulation of ghrelin axis influences the growth of colonic and prostatic cancer cells in vitro. Pharmacological Reports, 2012, 64, 951-959.	1.5	19

#	Article	IF	Citations
19	Immunohistochemical detection of FSH receptors in pituitary adenomas and adrenal tumors. Folia Histochemica Et Cytobiologica, 2012, 50, 325-330.	0.6	12
20	Angiotensins Inhibit Cell Growth in GH3 Lactosomatotroph Pituitary Tumor Cell Culture: A Possible Involvement of the p44/42 and p38 MAPK Pathways. Scientific World Journal, The, 2012, 2012, 1-10.	0.8	2
21	The Involvement of Angiotensin Type 1 and Type 2 Receptors in Estrogen-Induced Cell Proliferation and Vascular Endothelial Growth Factor Expression in the Rat Anterior Pituitary. Scientific World Journal, The, 2012, 2012, 1-9.	0.8	4
22	The effects of angiotensin peptides and angiotensin receptor antagonists on the cell growth and angiogenic activity of GH3 lactosomatotroph cells in vitro. Endocrine, 2012, 42, 88-96.	1.1	8
23	Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine, 2011, 55, 56-61.	1.4	23
24	Osteopontin and Endostatin Concentrations in Peripheral Blood of Patients with Adrenal Tumors Undergoing Unilateral Adrenalectomy. European Surgical Research, 2011, 47, 168-172.	0.6	1
25	The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors. , 2011, , 241-272.		0
26	Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell and Tissue Research, 2010, 340, 371-379.	1.5	17
27	Decreased 1-25 Dihydroxyvitamin D3 Concentration in Peripheral Blood Serum of Patients with Thyroid Cancer. Archives of Medical Research, 2010, 41, 190-194.	1.5	47
28	Reply: Decreased 1-25 Dihydroxyvitamin D3 Concentration in Peripheral Blood Serum of Patients with Thyroid Cancer. Archives of Medical Research, 2010, 41, 393.	1.5	0
29	Serum Concentrations of TNF $\hat{l}_{\pm}$ and Its Soluble Receptors in Patients with Adrenal Tumors Treated by Surgery. International Journal of Molecular Sciences, 2010, 11, 2281-2290.	1.8	3
30	Stimulatory effect of growth hormone–releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. Neuropeptides, 2009, 43, 397-400.	0.9	10
31	Peripheral blood concentrations of vascular endothelial growth factor and its soluble receptors (R1) Tj ETQq1 1 9-13.	0.784314 0.3	rgBT /Overlo
32	Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbeck's Archives of Surgery, 2008, 393, 275-280.	0.8	13
33	Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro. Cancer Letters, 2008, 268, 120-128.	3.2	8
34	Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 335-341.	1.4	13
35	The relationship between early recanalization and serum NT-proBNP levels in patients with a first ST-segment elevation myocardial infarction treated with primary coronary angioplasty. Acta Cardiologica, 2007, 62, 479-484.	0.3	2
36	Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine, 2006, 36, 291-295.	1.4	32

#	Article	IF	Citations
37	Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sciences, 2006, 78, 2558-2563.	2.0	62
38	Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats. Life Sciences, 2006, 79, 1741-1748.	2.0	2
39	The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 237-254.	0.8	13
40	The relationship between features of metabolic syndrome and blood adipocytokine concentrations in the morbid obese patients during dynamic weight loss. Open Medicine (Poland), 2006, 1, 136-147.	0.6	0
41	Effect of thalidomide on cell proliferation, prolactin, and VEGF secretion by oestrogen-induced pituitary rat prolactinoma in primary cell culture. Frontiers in Neuroendocrinology, 2006, 27, 27.	2.5	0
42	Serum vascular endothelial growth factor and its receptor level in patients with chronic obstructive pulmonary disease. European Cytokine Network, 2006, 17, 75-9.	1.1	12
43	Angiogenic and anti-angiogenic factors in adrenal tumours. Endokrynologia Polska, 2006, 57, 633-40.	0.3	2
44	Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas. Pituitary, 2005, 8, 163-168.	1.6	12
45	Growth Hormone Replacement Decreases Plasma Levels of Matrix Metalloproteinases (2 and 9) and Vascular Endothelial Growth Factor in Growth Hormone–Deficient Individuals. Circulation, 2004, 109, 2405-2410.	1.6	27
46	Effect of growth hormone-releasing hormone (GHRH) and GHRH antagonist (MZ-4-71) on interferon- $\hat{l}^3$ secretion from human peripheral blood mononuclear cells in vitro. Neuropeptides, 2004, 38, 35-39.	0.9	5
47	GH–RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. Life Sciences, 2003, 72, 2473-2479.	2.0	13
48	Evaluation of the Levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in Serum of Patients with Thyroid Cancer. Recent Results in Cancer Research, 2003, 162, 189-194.	1.8	27
49	Matrix Metalloproteinases, Tissue Inhibitors of Matrix Metalloproteinases and Angiogenic Cytokines in Peripheral Blood of Patients with Thyroid Cancer. Thyroid, 2002, 12, 655-662.	2.4	54
50	Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus, 2002, 11, 348-355.	0.8	40
51	Angiogenesis of endocrine gland tumoursnew molecular targets in diagnostics and therapy. European Journal of Endocrinology, 2002, 146, 143-151.	1.9	20
52	Octreotide Inhibits the Secretion of Interleukin-12 from Mononuclear Cells in Human Peripheral Blood (PBMCs) In Vitro1. Hormone and Metabolic Research, 2001, 33, 689-690.	0.7	6
53	Effects of Gn-RH, TRH, and CRF administration on plasma leptin levels in lean and obese women. Neuropeptides, 2000, 34, 89-97.	0.9	14
54	Pituitary–adrenocortical responses to the chronic administration of granulocyte colony-stimulating factor in rats. Journal of Neuroimmunology, 2000, 102, 73-78.	1.1	8

#	Article	IF	CITATIONS
55	Somatostatin (SOM) and Octreotide (OCT) Inhibit the Secretion of Interleukin-8 (IL-8) from Human Peripheral Blood Mononuclear Cells (PBMC)In Vitro*. Hormone and Metabolic Research, 2000, 32, 337-338.	0.7	4
56	Effect of Somatostatin and Octreotide on Proliferation and Vascular Endothelial Growth Factor Secretion from Murine Endothelial Cell Line (HECa10) Culture. Biochemical and Biophysical Research Communications, 2000, 268, 567-571.	1.0	50
57	Influence of granulocyte-macrophage colony stimulating factor on pituitary-adrenal axis (PAA) in rats in vivo. Pituitary, 1999, 2, 211-216.	1.6	9
58	Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunology Letters, 1998, 60, 143-148.	1.1	18
59	Effects of hCG and $\hat{l}^2$ -hCG on IL-2 and sIL-2R secretion from human peripheral blood mononuclear cells: A dose-response study in vitro. Immunology Letters, 1997, 59, 29-33.	1.1	16
60	Tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and slL-6R) serum levels in systemic lupus erythematodes. Mediators of Inflammation, 1996, 5, 435-441.	1.4	12
61	Evaluation of Interleukins, ACTH, Cortisol and Prolactin Concentrations in the Blood of Patients with Parkinson's Disease. NeuroImmunoModulation, 1996, 3, 131-134.	0.9	105
62	Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. Journal of Endocrinology, 1996, 150, 99-106.	1.2	57
63	The Mutual Effect of Dehydroepiandrosterone and Dexamethasone on Interleukin-8 Release from Human Peripheral Blood Mononuclear Cells CulturedIn Vitro. Hormone and Metabolic Research, 1996, 28, 570-571.	0.7	0
64	Somatostatin (SRIF) stimulates the release of interleukin-6 (IL-6) from human peripheral blood monocytes (PBM) in vitro. Neuropeptides, 1995, 29, 77-81.	0.9	26
65	Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on melatonin secretion in rats In vivo and in vitro studies. Journal of Neuroimmunology, 1995, 56, 187-190.	1.1	18
66	Interleukin- $1\hat{l}^2$ stimulates cell proliferation in the intermediate lobe of the rat pituitary gland. Journal of Endocrinology, 1994, 140, 337-341.	1.2	18
67	FSH and LH Induce Interleukin-6 (IL-6) Release from Human Peripheral Blood Monocytes Cultures <i>In Vitro</i> I). Hormone and Metabolic Research, 1994, 26, 438-439.	0.7	11
68	Inhibition of Rat Pituitary Tumor Cell Proliferation by Benzodiazepines in vitro. Neuroendocrinology, 1994, 59, 92-96.	1.2	32
69	Hypothalamic-Pituitary-Thyroid Axis and the Immune System. NeuroImmunoModulation, 1994, 1, 149-152.	0.9	27
70	Increased interleukin-2 levels during standard TRH test in man. Neuropeptides, 1994, 27, 151-156.	0.9	16
71	Stimulatory Effect of Angiotensin II on the Proliferation of Mouse Spleen Lymphocytes in vitro Is Mediated via Both Types of Angiotensin II Receptors. Biochemical and Biophysical Research Communications, 1994, 198, 1034-1039.	1.0	37
72	The evidence of thyroliberin/triiodothyronin control of TSH secretory response from human peripheral blood monocytes cultured in vitro. Neuropeptides, 1993, 25, 31-34.	0.9	16

#	Article	IF	CITATIONS
73	Immunomodulatory properties of diazepam-binding inhibitor: Effect on human interleukin-6 secretion, lymphocyte proliferation and natural killer cell activity in vitro. Neuropeptides, 1993, 25, 207-211.	0.9	12
74	Stimulatory Effect of Thyrotropin (TSH) on Interleukin-2 (IL-2) Release from Human Peripheral Blood Lymphocytes. Hormone and Metabolic Research, 1993, 25, 598-599.	0.7	17
75	Effects of somatostatin on inositol-1,4,5-trisphosphate content in mouse spleen lymphocytes. Comparative Biochemistry and Physiology A, Comparative Physiology, 1992, 101, 661-664.	0.7	7
76	Inhibitory effect of porphyrins on the proliferation of mouse spleen lymphocytes in vitro. Biochemical and Biophysical Research Communications, 1991, 174, 313-322.	1.0	9
77	Inhibitory effect of thyrotropin releasing hormone on spontaneous proliferation of mouse spleen lymphocytes in vitro. Biochemical and Biophysical Research Communications, 1991, 181, 562-565.	1.0	5
78	The effect of nerve growth factor on DNA synthesis, cyclic AMP and cyclic GMP accumulation by mouse spleen lymphocytes. International Journal of Immunopharmacology, 1991, 13, 51-56.	1.1	11
79	Effect of Amantadine on Prolactin Secretion, Pituitary DNA Synthesis and <sup>3</sup> H-Spiperone Binding in Male Estrogen-Treated Rats. Neuroendocrinology, 1990, 51, 632-636.	1.2	2
80	Effects of calcium channel modulators on the proliferation of mouse spleen lymphocytesin vitro. Agents and Actions, 1990, 29, 254-258.	0.7	11
81	Effect of Growth Hormone-Releasing Hormone on Human Peripheral Blood Leukocyte Chemotaxis and Migration in Normal Subjects. Neuroendocrinology, 1989, 50, 236-239.	1.2	24
82	Enhancement of human lymphocyte natural killer activity by somatostatin. Neuropeptides, 1989, 13, 75-77.	0.9	19
83	Effect of benzodiazepines on the proliferation of mouse spleen lymphocytes in vitro. Journal of Neural Transmission, 1988, 73, 161-166.	1.4	37
84	Effects of two neuropeptides, somatoliberin (GRF) and corticoliberin (CRF), on human lymphocyte natural killer activity. Brain, Behavior, and Immunity, 1988, 2, 50-56.	2.0	35
85	Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 643-645.	0.9	5
86	Immunomodulatory Action of Somatostatin. Annals of the New York Academy of Sciences, 1987, 496, 233-239.	1.8	39
87	Effects of diazepam on cell proliferation in cerebral cortex, anterior pituitary and thymus of developing rats. Life Sciences, 1987, 40, 1131-1135.	2.0	19
88	Somatostatin and its analog enhance the formation of human leukocyte migration inhibiting factor: Further evidence for immunomodulatory action of somatostatin. Peptides, 1987, 8, 951-952.	1.2	19
89	Epidermal growth factor in human cerebrospinal fluid: reduced levels in amyotrophic lateral sclerosis. Journal of Neurology, 1986, 233, 376-377.	1.8	17
90	Enhancement of estradiol-induced DNA synthesis in the anterior pituitary gland by the peripheral-type benzodiazepine receptor ligand RO 5-4864. Journal of Neural Transmission, 1986, 66, 303-307.	1.4	5

#	Article	IF	Citations
91	Increased CSF Levels of Somatostatin in Patients with Brain Tumours and Intracranial Hypertension. Hormone and Metabolic Research, 1986, 18, 555-557.	0.7	6
92	Effect of somatostatin on the proliferation of mouse spleen lymphocytes in, vitro. Biochemical and Biophysical Research Communications, 1985, 129, 52-55.	1.0	79
93	The finding and significance of spermidine and spermine in fraction 5. Biochemical and Biophysical Research Communications, 1982, 108, 1482-1487.	1.0	2
94	Dopamine increases cyclic AMP concentration in the rat spleen lymphocytes in vitro. Biochemical and Biophysical Research Communications, 1981, 101, 1057-1063.	1.0	11
95	The finding and partial purification and characterization of thymone C. Biochemical and Biophysical Research Communications, 1981, 98, 115-121.	1.0	3
96	LHRH INHIBITS [3H]THYMIDINE INCORPORATION BY PITUITARY CELLS CULTURED IN VITRO. Endocrinology, 1981, 109, 1784-1786.	1.4	10
97	Serum Gastrin Levels in Patients with Acromegaly. Hormone and Metabolic Research, 1981, 13, 714-715.	0.7	0
98	Isolation of glutathione from bovine thymus and its significance to research relevant to immune systems. Biochemical and Biophysical Research Communications, 1980, 97, 590-594.	1.0	5
99	Isolation of thymone A from bovine thymus partial chemical and biological characterization. Biochemical and Biophysical Research Communications, 1980, 97, 595-600.	1.0	5
100	Isolation, partial chemical and biological characterization of thymone B. Biochemical and Biophysical Research Communications, 1980, 97, 601-606.	1.0	5
101	Effects of fibroblast growth factor and bromocriptine on the mitotic activity of the anterior pituitary gland in organ culture. Cell and Tissue Research, 1979, 202, 165-169.	1.5	8
102	Dopamine blockade of the thyroliberin-induced cyclic AMP accumulation in rat anterior pituitary. Journal of Neural Transmission, 1979, 45, 75-79.	1.4	9
103	Somatostatin inhibits the mitogenic effect of thyroliberin. Experientia, 1978, 34, 271-272.	1.2	23
104	Effects of pimozide and bromocriptine on anterior pituitary cell proliferation. Journal of Neural Transmission, 1978, 42, 239-244.	1.4	26
105	Effect of castration on the concentration of adenosine $3\hat{a}\in ^2$ , $5\hat{a}\in ^2$ -monophosphate in the rat pineal organ. Journal of Neural Transmission, 1978, 42, 145-149.	1.4	10
106	DIRECT ANTIPROLIFERATIVE EFFECT OF DOPAMINE AGONISTS ON THE ANTERIOR PITUITARY GLAND IN ORGAN CULTURE. Journal of Endocrinology, 1978, 79, 245-246.	1.2	31
107	Influence of Cholinergic Receptor Blockade and Stimulation on the Anterior Pituitary Mitotic Activity. Neuroendocrinology, 1978, 26, 85-92.	1.2	8
108	EFFECTS OF PIMOZIDE AND BROMOCRIPTINE ON THE PROLIFERATION OF RAT PITUITARY PARS INTERMEDIA CELLS. Journal of Endocrinology, 1977, 75, 443-444.	1,2	24

#	Article	IF	CITATIONS
109	Influence of castration followed by administration of LH-RH on the ultrastructure of rat pinealocytes. Cell and Tissue Research, 1976, 167, 325-339.	1.5	54
110	Thyroxine Inhibition of the Proliferative Response of the Anterior Pituitary to Thyrotropin Releasing Hormone <i>in vitro</i> . Neuroendocrinology, 1975, 18, 277-280.	1.2	18
111	Effects of pentosan polysulfate sodium on the estrogen-induced pituitary prolactinoma in Fischer 344 rats. Oncology Reports, $0$ , , .	1.2	0